Welcome to our dedicated page for Xenon Pharmaceut news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceut stock.
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company whose news flow centers on clinical progress, scientific data, and corporate developments in neurology and psychiatry. The company is advancing azetukalner, a novel, potent, selective Kv7 potassium channel opener in Phase 3 clinical trials for epilepsy, major depressive disorder (MDD), and bipolar depression (BPD), alongside early-stage Kv7 and NaV1.7 programs in pain and a NaV1.1 program in Dravet syndrome.
News related to XENE often covers clinical milestones, such as enrollment updates and anticipated topline data from Phase 3 studies like X-TOLE2 and X-TOLE3 in focal onset seizures (FOS), X-ACKT in primary generalized tonic-clonic seizures (PGTCS), and the X-NOVA and X-CEED programs in MDD and BPD. Xenon also issues press releases on long-term X-TOLE open-label extension (OLE) data, which include multi-year seizure frequency reductions and analyses of seizure freedom patterns with extended azetukalner treatment.
Investors and clinicians following XENE can expect scientific conference coverage from meetings such as the American Epilepsy Society Annual Meeting, where Xenon presents posters on epilepsy outcomes, depression burden in epilepsy, and pre-clinical data from its NaV1.1 Dravet syndrome program. Additional news items include corporate updates like quarterly financial results, investor conference presentations, investor webinars, and executive appointments, such as the appointment of a Chief Financial Officer in connection with anticipated commercialization activities.
Bookmark this page to monitor Xenon’s latest announcements on its Phase 3 epilepsy and mood disorder programs, early-stage pain pipeline, partnered work with Neurocrine Biosciences, and ongoing regulatory and investor communications.
Xenon Pharmaceuticals (NASDAQ:XENE) has appointed Darren Cline as Chief Commercial Officer to lead the company's transition to a commercial-stage organization. Cline brings over 30 years of experience in commercial strategy and operations, notably from his roles at Epygenix Therapeutics and GW Pharmaceuticals, where he successfully commercialized Epidiolex.
Cline will primarily focus on the commercial strategy for azetukalner, Xenon's lead Phase 3 candidate being studied for three indications: epilepsy, major depressive disorder (MDD), and bipolar depression (BPD). Phase 3 data is expected in early 2026. The company granted Cline stock options for 185,800 shares at $31.49 per share and 6,200 performance share units as part of his compensation package.
Xenon Pharmaceuticals (Nasdaq: XENE) announced its participation in the upcoming 2025 RBC Capital Markets Global Healthcare Conference in New York. CEO Ian Mortimer will present a fireside chat on Wednesday, May 21, 2025, from 10:30-10:55 AM ET. The presentation will be available via webcast on Xenon's website.
Xenon is a neuroscience-focused biopharmaceutical company developing ion channel products for epilepsy and depression. Their lead candidate, azetukalner, is a Kv7 potassium channel opener in late-stage clinical development for multiple indications.
Xenon Pharmaceuticals (Nasdaq: XENE) has scheduled to release its first quarter 2025 financial results and provide a business update after U.S. market close on Monday, May 12, 2025. The company will host a conference call at 4:30 pm Eastern Time on the same day.
Xenon is a neuroscience-focused biopharmaceutical company developing ion channel products for epilepsy and depression. Their lead candidate, azetukalner, is a Kv7 potassium channel opener in late-stage clinical development for multiple indications.
Xenon Pharmaceuticals (NASDAQ: XENE) has announced equity inducement grants to four new non-officer employees, consisting of 78,600 share options and 1,800 performance share units (PSUs). The grants, effective May 2, 2025, were approved by the Compensation Committee and comply with Nasdaq Listing Rule 5635(c)(4). The share options have an exercise price of $38.28 per common share, vesting over four years with a 10-year term. The PSUs will vest based on achieving predefined milestone-based objectives over approximately three years.
Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company developing ion channel products for epilepsy and depression. Their lead product, azetukalner, is a Kv7 potassium channel opener in late-stage clinical development for multiple indications.
Xenon Pharmaceuticals (XENE) has announced multiple presentations at the upcoming American Academy of Neurology Annual Meeting (AAN 2025) in San Diego. The company will showcase three key posters, highlighting significant progress in their epilepsy treatment research.
The main focus is on azetukalner, their novel Kv7 potassium channel opener, featuring 36-month long-term data from the ongoing X-TOLE open-label extension study in patients with focal onset seizures (FOS). The data demonstrates sustained monthly reduction in seizure frequency, impressive seizure freedom rates, and a consistent safety profile.
Additional presentations include an exploratory analysis showing reduced seizure frequency across four focal seizure subtypes, and patient survey findings regarding mental health and comorbidity burdens of FOS. The presentations will take place between April 5-9, 2025, with Xenon also hosting booth #1110 in the Exhibit Hall.
Xenon Pharmaceuticals (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company, has announced its participation in the upcoming Stifel 2025 Virtual CNS Forum, scheduled for March 18-19, 2025. The company will deliver a fireside chat presentation, which will be accessible via live audio webcast on the 'Investors' section of Xenon's website.
Xenon specializes in developing ion channel product portfolio targeting areas with high unmet medical needs, particularly epilepsy and depression. Their leading product, Azetukalner, is a novel Kv7 potassium channel opener currently in late-stage clinical development for multiple indications. This compound represents the most advanced, clinically validated potassium channel modulator in development.
Xenon Pharmaceuticals (XENE) has provided its Q4 and full year 2024 financial results and business update. The company's lead drug candidate azetukalner is advancing in multiple Phase 3 trials, with topline data for focal onset seizures expected in H2 2025. The company is expanding its neuropsychiatric programs, with the first of three Phase 3 trials for major depressive disorder underway and plans to initiate bipolar depression studies mid-year.
Financial highlights include: Cash position of $754.4 million as of December 31, 2024, expected to fund operations into 2027. R&D expenses increased to $210.4 million for 2024, up from $167.5 million in 2023. Net loss widened to $234.3 million in 2024 compared to $182.4 million in 2023.
The company announced CFO Sherry Aulin will step down on June 30, 2025. Additionally, Xenon's collaboration with Neurocrine Biosciences achieved a milestone with the initiation of a Phase 1 study of their Nav1.2/Nav1.6 inhibitor, triggering a $7.5 million payment.
FAQ
What is the current stock price of Xenon Pharmaceut (XENE)?
What is the market cap of Xenon Pharmaceut (XENE)?
